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Systems biologyerlap with a diverse array of other neurological disorders, suggesting common
molecular mechanisms. We conducted a large comparative analysis of the network of genes linked to autism
with those of 432 other neurological diseases to circumscribe a multi-disorder subcomponent of autism. We
leveraged the biological process and interaction properties of these multi-disorder autism genes to overcome
the across-the-board multiple hypothesis corrections that a purely data-driven approach requires. Using
prior knowledge of biological process, we identiﬁed 154 genes not previously linked to autism of which 42%
were signiﬁcantly differentially expressed in autistic individuals. Then, using prior knowledge from
interaction networks of disorders related to autism, we uncovered 334 new genes that interact with
published autism genes, of which 87% were signiﬁcantly differentially regulated in autistic individuals. Our
analysis provided a novel picture of autism from the perspective of related neurological disorders and
suggested a model by which prior knowledge of interaction networks can inform and focus genome-scale
studies of complex neurological disorders.
Published by Elsevier Inc.Introduction
Autism is a complex multigenic disorder with a wide range of
phenotypes. Although it is clear that the disorder is highly heritable,
the molecular agents responsible remain elusive and it remains
unclear whether the genetic component is a combination of a few
common variants, or of many rare variants [1]. More than 100 genes
have been tied to autism, each of which is involved in numerous
biological processes and in a variety of different molecular
interactions. It becomes daunting if at all manageable for a single
researcher to encompass the complexity of this autism gene space,
and perhaps for this reason, integration of this space into a
productive set of hypotheses has taken a backseat to investigations
of single genes or mechanisms. To date, these efforts have not
delivered highly accurate markers or proven targets for therapeutic
intervention.
As a result, autism remains a behavioral or symptomatic
diagnosis rather than a molecular diagnosis. The behavioral
manifestations include social anxiety and gaze avoidance, repeti-
tive movements and behaviors, hypersensitivity to touch, reduced
coordination, delayed speech and echolalia. Interestingly, several
of these symptoms overlap with other neurological disorders,
including Tuberous Sclerosis [2,3], Hypotonia [4], Rett Syndrome
and Fragile X syndrome. These behavioral similarities suggest that.
nc.there might be shared molecular mechanisms, at least in part. In
support of this suggestion, the causative genes for Fragile X and
Rett Syndrome have been linked to autism [5–7]. Interestingly
even though disorders like Fragile X are monogenic, their
behaviors can vary. For example, in Fragile X, behaviors range
from relatively mild learning disabilities to mental retardation,
speech impairments, and echolalia. The reason for this range is
most likely due in part to a network of interactions between the
genes linked to monogenic disorders and their direct or indirect
binding partners. In such a case, mutations in the causative gene
alter its interactions with neighboring genes that are required to
perform speciﬁc biological functions, and the effects of these
alterations become compounded when binding partners down-
stream of the causative agent are also mutated or otherwise
dysfunctional.
Therefore, it is the interaction network and set of biological
processes it performs rather than a single gene that effects
symptoms indicative of classically monogenic disorders [8–10].
Moreover, this suggests a testable hypothesis: disorders with
behavioral similarities to autism may have many genes in common
with autism. For example, this would imply signiﬁcant overlap in the
biological processes disordered in instances of Fragile X with the
behaviorally overlapping non-Fragile X causes of autism. By
quantifying this overlap at the level of molecular physiology we
aim to obtain a more complete understanding of the spectrum of
behaviors indicative of autism. Eventually, the comparison of autism
to other disorders of the central nervous system using symptoms,
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have an immediate impact our understanding of the disorder's
etiology. In this investigation, we compared autism to 432 other
neurological disorders at the levels of biological processes and
gene networks. By this comparative approach, we were able to
leverage information from related disorders to predict new genes
of possible importance to the etiology of autism. The ﬁgure of
merit that we use to validate our predictions is the capability of
ﬁnding signiﬁcance in high-throughout studies, in this instance,
transcriptome-scale expression proﬁling. We determined that the
focus provided by prior knowledge yields the speciﬁcity to overcome
the multiple hypothesis testing corrections that purely data-driven
approaches entail.
Results
The multi-disorder component of the autism network
Using OMIM and GeneCards we generated gene lists for 433
neurological disorders listed by NINDS as of December 2006. WeFig. 1.Maximum-parsimony based phylogeny of autism and related neurological disorders. T
disorders" or "Autism sibling group."selected a subset of the disorders that had 3 or more genes in
common with autism. By converting the gene lists into a matrix of
gene presence and absence we were able to generate a disorder
phylogeny that grouped autism together with 13 related disorders,
including Microcephaly, Mental Retardation, Ataxia, and Seizure
Disorder (Fig.1). We focused on the members of this autism sibling
group for subsequent analyses.
We used the tool STRING to construct gene networks for each
member of the autism sibling group in order to investigate genetic
overlaps with autism (summary of edge information available online
in Supplementary Table 1). Of the 127 genes in our candidate list for
autism, 66 have also been linked to at least one other autism sibling
disorder (Table 1). This multi-disorder gene set (MDAG) formed a
highly connected subcomponent of the complete autism network
(Fig. 2), suggesting that the genes in the MDAG share biological
function. To test this, we used the Explain™ System from BioBase,
which contains an abundance of manually reviewed information, to
identify signiﬁcant overrepresentation of MDAG genes in biological
processes. A total of 12 biological processes had signiﬁcant enrich-
ment following Bonferroni multiple test correction (Table 2).he group containing autism is highlighted and referred to in the text as "Autism sibling
Table 1
Multi-disorder autism gene set (MDAG). The 66 MDAG genes are highlighted in orange
within the autism network (Fig. 2) and are found in at least one autism sibling disorder
(Fig. 1)
Gene Neurological disorders
ABAT Tuberous sclerosis, autism, hypotonia, mental retardation
ACADL Autism, hypotonia
ADA Hypoxia, autism
ADM Hypoxia, autism
ADSL Microcephaly, autism, hypotonia, mental retardation
ALDH5A1 Ataxia, seizure disorder, autism, hypotonia, mental retardation
APOE Hypoxia, autism, tuberous sclerosis
ATP10A Angelman syndrome, microcephaly, ataxia, autism, hypotonia
ARX Microcephaly, spasticity, mental retardation
ASPG1 Autism, asperger syndrome
ASPG2 Autism, asperger syndrome
BTD Ataxia, hypotonia, mental retardation
CACNA1D Autism, Rett syndrome
CD69 Ataxia, autism
Infantile hypotonia, Angelman ayndrome, ataxia, Rett syndrome
CDKL5 Microcephaly, autism, hypotonia, mental retardation
CHRNA4 Autism, mental retardation
CHRNA7 Autism, mental retardation
DAB1 Autism, mental retardation
Seizure disorder, hypoxia, tuberous sclerosis, microcephaly, autism
DCX Mental retardation
DGCR Autism, mental retardation
DHCR7 Microcephaly, autism, hypotonia, mental retardation
DPYD Microcephaly, ataxia, autism, mental retardation
EXT1 Autism, mental retardation
EXT2 Autism, mental retardation
Fragile X, infantile hypotonia, ataxia, Rett syndrome, microcephaly
FMR1 Autism, hypotonia, mental retardation
FOXP2 Ataxia, autism
FXR1 Fragile X, autism, mental retardation
GABRA5 Angelman syndrome, autism
GABRB3 Angelman syndrome, ataxia, autism, mental retardation
GABRG2 Ataxia, seizure disorder, autism
GATA3 Hypoxia, autism
GLO1 Ataxia, autism
GRIN2A Hypoxia, autism
GRPR Autism, Rett syndrome, mental retardation
HOXA1 Asperger syndrome, autism, Rett syndrome, mental retardation
KIF1A Autism, tuberous sclerosis
MAGEL2 Angelman syndrome, autism, hypotonia, mental retardation
MAOA Autism, mental retardation
MAP2 Tuberous sclerosis, hypoxia, autism, Rett syndrome, mental retardation
MBD1 Autism, Rett syndrome
MBD2 Autism, Rett syndrome
Fragile X, infantile hypotonia, seizure disorder, Angelman syndrome,
spasticity, ataxia, Asperger syndrome, Rett syndrome, microcephaly,
MECP2 Tuberous sclerosis, autism, hypotonia, mental retardation
MED12 Fragile X, autism, mental retardation
MET Hypoxia, autism
MTF1 Hypoxia, autism
NDN Angelman syndrome, hypoxia, Rett syndrome, autism, hypotonia, mental
retardation
NDNL2 Angelman syndrome, autism, seizure disorder, spasticity, tuberous sclerosis,
microcephaly, autism
NF1 Mental metardation
NLGN3 Asperger syndrome, autism, mental retardation
NLGN4Y Asperger syndrome, Angelman syndrome, autism, mental retardation
NLGN4X Asperger syndrome, autism, mental retardation
NTF4 Autism, mental retardation
PAX3 Autism, mental retardation
PTEN Ataxia, seizure disorder, hypoxia, autism
RELN Ataxia, tuberous sclerosis, autism, hypotonia, mental retardation
SCN1A Ataxia, autism
SDC2 Autism, mental retardation
SLC40A1 Ataxia, autism
SLC6A4 Fragile X, hypoxia, Asperger syndrome, tuberous sclerosis, autism, Rett
syndrome, mental retardation
SNRPN Angelman syndrome, Rett syndrome, microcephaly, autism, hypotonia,
mental retardation
SSTR5 Autism, tuberous sclerosis
TH Hypoxia, spasticity, autism, Rett syndrome, infantile hypotonia
TPH1 Autism, Rett syndrome, mental retardation
TSC1 Tuberous sclerosis, autism, mental retardation
Angelman syndrome, spasticity, ataxia, hypoxia, Rett syndrome,
Table 1 (continued)
Gene Neurological disorders
UBE3A Microcephaly, autism, hypotonia, mental retardation
VLDLR Fragile X, ataxia, hypoxia, autism
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One possible reason for the large extent of behavioral overlap
between autism and many of the disorders in the autism sibling
group may be the result of context speciﬁc dysregulation of any or
all of the processes for which the MDAG is enriched. Thus, other
autism sibling disorder-linked genes that are known to be involved
in any of the 12 signiﬁcantly enriched processes but that have not
yet been implicated in autism may represent viable autism
candidates. To address this hypothesis, we mined the gene lists of
the autism sibling disorders and identiﬁed a non-redundant set of
154 process-based candidates (PBC). The process “transmission of
nerve impulse” was not found among the genes in the autism sibling
disorders. All other enriched processes yielded 2 or more unique
predictions all of which are involved in at least two of the autism
sibling disorders, but not found in our original autism candidate list
(Table 3; complete list of 154 process-based candidates is available
as online Supplementary Table 2).
To empirically test the importance of the PBC in autism, we asked
whether any exhibited signiﬁcantly different gene expression in
autistic patients in comparison to controls. As wewere only concerned
with testing the PBC, we performed multiple test correction on just
these 154 hypotheses. Speciﬁcally we calculated q values, an FDR-
based measure of signiﬁcance, and discovered that 64 of the 154, 42%,
were signiﬁcantly differentially regulated with q≤0.05 (Table 3). By
recalculating q values for 1000 randomly constructed gene sets of size
154 (drawing from the entire set of genes sampled in the microarray
experiment used), we determined that this frequency of signiﬁcant
features was unlikely to occur by chance (pb0.01).
Intersecting the autism and sibling disorder networks: network-driven
search for new autism candidates
Next, using data derived from STRING [11], we constructed the
network of genes for every autism sibling disorder to study the
interactions surrounding members of the MDAG, speciﬁcally focusing
on direct neighbors toMDAG genes that were not present in our original
autism gene list (e.g., as shown in Fig. 3). This analysis found 334 genes
thatweredirectly connected to amemberof theMDAG, but not known to
be of importance in autism. Of these, 198 occurred in 1 autism sibling
disorder, 83 occurred in 2, 35 in 3, 9 in 4 disorders and 9 in 5with 5 being
the maximum extent of overlap (Table 4 summarizes the top 40 genes
after ranking on the number of disorders to which the genes have been
linked; a full list is available online as Supplementary Table 3). These
network-based candidates contained several genes that have some pre-
established association to neurological dysfunction. For example
L1CAM's functions include guidance of neurite outgrowth in develop-
ment, neuronal cell migration, axon bundling, synaptogenesis, myelina-
tion, andneuronal cell survival and it is amonga familyof genes thatwere
recently shown tohave roles in neurological dysfunction [12]. In addition,
BDNF has been associated with autism [13], and SLC6A8 has established
ties to autism via dysfunction of creatine transporter activities [14].
We used the samemRNA expression data as above to test if the 334
network-based candidateswere differential expressedwithin autistics
when compared to control samples. Correcting only for the 334
hypotheses being tested, we found that 289 had q values less than 0.05
(all NBC q values available in Supplementary Table 3). That is, ~87% of
the genes predicted via our comparative analysis of the disease
networks turned out to be signiﬁcantly differentially regulated in
autism in comparison to controls. To determine if this percentage could
Fig. 2. The complete network of autism candidate genes. The autism network with all multi-disorder autism genes (MDAG) highlighted. These are genes that occur in one or more of
the autism sibling disorders, which are circumscribed in Fig. 1.
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1000 groups of 334 genes by randomly sampling from the complete set
of autism expression data and recalculated q values. Themean number
of signiﬁcant features within these randomly constructed genes sets
was 31, indicating that our observed value of 289was highly unlikely to
occur by chance (pb0.01).
Intersection of the network and process-based approaches to prioritize
genes for further study in autism
We can intersect our two computational approaches to triangulate
on the set of genes that were independently predicted and veriﬁed by
both strategies and reduce the size of the intersection by ﬁltering out
those genes that occur in 2 or less autism sibling disorders. This is
predicated on the assumption that genes with multiple independent
associations to neurological disorders aremore likely to have an impact
on normal neurological development and function. A total of 9 genes
satisﬁed these criteria and were ‘SLC16A2’, ‘SLC6A8’, ‘OPHN1’, ‘FXN’,
‘AR’, ‘L1CAM’, ‘FLNA’, ‘MYO5A’, ‘PAFAH1B1.’ All were found to be
differentially expressed in one of the two tests for differential
expression and all occur in 3 or more autism sibling disorders. We
performed a process enrichment analysis to determinewhether these 9genes were enriched for a particular set of biological processes.
Although no process was signiﬁcant following multiple test correction,
a total of 14 processes had uncorrected p values below 0.05 and
included cell and cytoskeletal organization and biogenesis, cellmotility,
and cell communication (Table 5). That the two analytical strategies had
appreciable overlap was not entirely surprising, as we should expect
genes to interact if they are involved in the same biological processes.
Nonetheless, triangulation on the same genes using independent
approaches and different data sources provides an internal consistency
check and suggests that further investigations of these 9 genes are
warranted. Recent work suggested that malformations in cytoskeletal
organization may contribute to neuronal migration and lead to
neurological impairments [15]. It is possible that similar defects are
occurring in autistic patients via dysregulation of these 9 genes or
combinations thereof. Further study, such as experiments to determine
whether single gene perturbations entail coordinated changes among
any of these genes would help to conﬁrm this hypothesis.
Discussion
In this study, we conducted a comparative analysis of autism
and 432 other neurological disorders listed by the National
Table 2
Biological processes for which the multi-disorder component of the autism gene set
(MDAG) were enriched
Biological process P value MDAG genes
Transmission of nerve impulse 3.00E-11 ABAT, ALDH5A1, APOE, CHRNA4, CHRNA7,
GABRA5, GABRB3, GABRG2, GATA3, GRIN2A,
MAOA, MET, NF1, NTF4, SCN1A, SLC6A4, TH,
TPH1, TSC1
Nervous system development 3.29E-11 ALDH5A1, APOE, ARX, BTD, CHRNA4, DAB1,
DCX, FMR1, FOXP2, GABRA5, GATA3, GRIN2A,
HOXA1, MAP2, MECP2, MET, NDN, NF1, PAX3,
PTEN, RELN, TSC1, UBE3A, VLDLR
Synaptic transmission 7.68E-10 ABAT, ALDH5A1, APOE, CHRNA4, CHRNA7,
GABRA5, GABRB3, GABRG2, GATA3, GRIN2A,
MAOA, MET, NF1, NTF4, SLC6A4, TH, TPH1
Cell–cell signaling 3.12E-09 ABAT, ADM, ALDH5A1, APOE, CHRNA4,
CHRNA7, GABRA5, GABRB3, GABRG2, GATA3,
GRIN2A, MAOA, MET, NF1, NTF4, SCN1A,
SLC6A4, SSTR5, TH, TPH1, TSC1
Brain development 2.64E-06 ARX, DAB1, DCX, FOXP2, GABRA5, HOXA1,
MET, NF1, RELN, TSC1, UBE3A
Generation of neurons 2.43E-05 APOE, ARX, DAB1, DCX, MAP2, MECP2, MET,
NDN, NF1, NTF4, PTEN, RELN, VLDLR
Regulation of cell proliferation 2.45E-04 ADM, ARX, CHRNA7, DHCR7, FOXP2, GRPR,
MECP2, MET, NDN, NF1, PAX3, PTEN,
SSTR5, TSC1
Cell migration 3.93E-03 ARX, DAB1, DCX, MET, NDN, NF1, PAX3, PTEN,
RELN, VLDLR
Homeostasis 1.90E-02 ADM, APOE, ARX, CHRNA4, CHRNA7, GRIN2A,
MBD1, NDN, NF1, SCN1A, SLC40A1, SSTR5, TH
Cell morphogenesis 1.94E-02 APOE, ARX, ATP10A, DCX, MAP2, MECP2,
NDN, PTEN, RELN, TSC1
Ion transport 2.74E-02 ARX, CACNA1D, CHRNA4, CHRNA7, GABRA5,
GABRB3, GABRG2, GRIN2A, MECP2, MET,
SCN1A, SLC40A1, TSC1
Cell differentiation 4.35E-02 ADM, APOE, ARX, DAB1, DCX, DHCR7, EXT2,
FXR1, GATA3, GLO1, GRIN2A, MAP2, MECP2,
MET, NDN, NF1, NTF4, PAX3, PTEN, RELN,
TSC1, VLDLR
Identities of the MDAG genes overrepresented in the processes as well as the corrected
p value for the enrichment scores are provided. Enrichment was calculated in the
ExPlainTm 2.3 Tool from BioBase (www.biobase-international.com) and p values were
adjusted by the Bonferroni method.
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focusing on a set of disorders that appeared to be most closely
related to autism (autism sibling disorders, Fig. 1), we found that
more than half of the published autism genes have implicated in
related neurological disorders. This conﬁrmed that there is
molecular overlap and suggested that these disorders may share
molecular mechanisms that could be informative to our under-
standing of the genetic etiology of autism. The multi-disorder
component of the autism network (MDAG) was highly connected
and enriched for a small number of biologically informative
processes, including synaptic transmission, and central nervous
system development.
Motivated by these ﬁndings we devised two analytical strategies
to test whether information from related disorders could provide
meaningful focus to the genome-wide search for autism gene
candidates. The ﬁrst, a process-based strategy, was predicated on
the assumption that processes for which the MDAG genes were
enriched are generally important for neurological dysfunction. It is
further predicated on the hypothesis that genes involved in these
processes that have been linked to one or more autism sibling
disorder, but that have not yet been implicated in autism, should be
autism gene candidates. We tested this hypothesis using available
whole-genomic expression data from 17 autistics with early onset
and 12 controls from the general population (data from [16]) and
found that 42% of the predictions were under signiﬁcant differential
expression in autistic individuals. The fact that they have beenimplicated in neurological dysfunction and involved in what appear
to be important autism processes together makes these genes
appealing new leads for the understanding the molecular pathology
of autism.
The second strategy was grounded in the now mainstream
understanding that protein interaction networks can provide
valuable and often serendipitous leads for disease causing agents
[17–22]. In our network-based strategy, rather than look at the
entire protein interaction network, we ﬁltered the set of all
interactions to MDAG genes such that they included only those
proteins present in the list of autism sibling disorders, but absent
from out list of published autism candidates. This strategy
uncovered 334, of which 87% were found to be signiﬁcantly
differentially expressed in autistic when compared to controls. This
network-based strategy revealed that there are a large number of
differences in the interaction networks of these related neurolo-
gical disorders, even one step removed from those genes that are
shared among them (the MDAG). While the differences may reﬂect
real mechanistic differences between autism and its sibling
disorders, given the high number found to be differentially
regulated here, it is more likely that at least a fraction of them
represent key gaps in our understanding of autism.
In both analytical strategies, we were able to use the prior
knowledge from external resources, in this case from biological
processes and interaction networks, to yield focused sets of genes
hypothesized to be under differential regulation in autistics.
From the methodological perspective, it bears emphasis that in the
absence of such prior knowledge many of the genes measured on
the small number of patients in this study had False Discovery
RatesN 0.5. This a frequent circumstance in instances of weak
signals and large background noise in many transcriptome-level
experiments [23–25]. In contrast, with the application of prior
knowledge, the majority of the genes tested had an FDRb0.05. This
inversion of the usual speciﬁcity problem at the genome-scale
points to a promising fusion of knowledge-driven and data-driven
methods.
Finally, although the networks evaluated herein should be
considered preliminary, how they intersect and in particular how
the networks of related CNS-associated disorders overlap with
autism may be an important way to begin to understand the
genetics of different parts of the phenotypic spectrum of autism.
Fig. 4 represents a ﬁrst attempt at circumscribing subcomponents
of the entire autism network that largely correspond to single
related neurological disorders. This disorder-centric view of autism
may eventually provide more direct clues to the genetic basis of
the spectrum of behaviors indicative of autism. Qualitatively this
ﬁgure reveals clusters of autism genes a majority of which are
linked to a single autism-related neurological disorder, namely
Mental Retardation, Tuberous Sclerosis, Angelman Syndrome, and
Fragile X. This hints at the possibility that further comparative
analysis may provide a way to understand the genotype–phenotype
map for autism's diverse symptom spectrum. Also these circum-
scriptions could help to serve as a map to research done on related
neurological disorders that may be directly relevant to our
understanding of the etiology of autism. Future work, including
the evaluation of more neurological disorders within Fig. 1 and
disorders other than those that affect the CNS may help to rank
and reorder genes that have been implicated in autism to date, and
possibly reveal new genes worth investigating.
Materials and methods
Diseases and gene lists
We downloaded a complete set of 433 neurological disorders
from the National Institute of Neurological Disorders and Strokes
Table 3
The 64 process-based candidates found to be signiﬁcantly differentially regulated in autistic individuals when compared to controls
Gene P
value
Q value Processes Disorders
FN1 0 0 Cell migration Hypoxia, Asperger syndrome
AFF2 0.0121 0.02294 Brain development Fragile X, mental retardation
ANGPT1 0.0025 0.02294 Cell differentiation Hypoxia
ATXN3 0.0124 0.02294 Nervous system development, synaptic transmission, transmission of nerve
impulse
Ataxia, hypotonia
BMP2 0.0091 0.02294 Cell–cell signaling Hypoxia
CHL1 0.0016 0.02294 Cell differentiation, nervous system development Ataxia, microcephaly, mental retardation
DYRK1A 0.0157 0.02294 Nervous system development Hypotonia, mental retardation
EDNRB 0.0043 0.02294 Nervous system development Microcephaly, hypoxia
FHL1 0.0037 0.02294 Cell differentiation Fragile X
FXN 0.0034 0.02294 Synaptic transmission, transmission of nerve impulse Ataxia, fragile X, mental retardation
GNPTAB 0.005 0.02294 Cell differentiation Hypotonia
GPM6B 0.0067 0.02294 Cell differentiation Rett syndrome
HIF1A 0.0007 0.02294 Homeostasis Hypoxia
ITGB1 0.0023 0.02294 Cell migration Hypoxia
KCNMA1 0.015 0.02294 Ion transport, synaptic transmission, transmission of nerve impulse Ataxia, hypoxia
MYOD1 0.0029 0.02294 Cell differentiation Hypoxia
NRP1 0.0132 0.02294 Cell differentiation, cell–cell signaling Hypoxia
OPHN1 0.007 0.02294 nervous system development Ataxia, hypotonia, mental retardation
PAFAH1B1 0.0092 0.02294 Cell differentiation, ion transport, nervous system development Microcephaly, mental retardation, tuberous sclerosis, hypotonia,
spasticity tuberous sclerosis
RELN 0.0146 0.02294 Brain development Ataxia, major depression, tuberous sclerosis, hypotonia, mental
retardation
SDHD 0.0015 0.02294 Ion transport Angelman syndrome
SLC1A1 0.0028 0.02294 Ion transport, synaptic transmission, transmission of nerve impulse Ataxia, hypoxia
TGFB2 0.0137 0.02294 Generation of neurons, cell morphogenesis Hypoxia
TP53 0.0079 0.02294 Cell differentiation Ataxia, fragile X, hypoxia
ZIC2 0.0126 0.02294 Brain development, cell differentiation Microcephaly
ANGPT2 0.0186 0.02376 Cell differentiation Hypoxia
AR 0.0189 0.02376 Ion transport, cell–cell signaling Ataxia, fragile X, hypoxia
NOS1 0.0182 0.02376 cell–cell signaling Major depression, hypoxia
SIX3 0.0211 0.0252 Brain development Microcephaly
CACNA1A 0.0224 0.02524 Ion transport, nervous system development, synaptic transmission,
transmission of nerve impulse
Ataxia, major depression, mental retardation
PURA 0.0228 0.02524 Cell differentiation Fragile X
ESR2 0.0241 0.02568 Cell–cell signaling Hypoxia
ITGB2 0.0249 0.02568 Cell–cell signaling Hypoxia
CREBBP 0.0266 0.02619 Homeostasis Ataxia, hypoxia, mental retardation
ZEB2 0.0271 0.02619 Nervous system development Microcephaly, mental retardation
ATP2A2 0.0285 0.0267 Ion transport Hypoxia, mental retardation
S100B 0.0369 0.03335 Nervous system development Major depression, hypoxia, mental retardation
HBA2 0.0405 0.03381 Ion transport Major depression, hypoxia, tuberous sclerosis, mental retardation
PPT1 0.0403 0.03381 Brain development, nervous system development Major depression, mental retardation, spasticity
TAL1 0.0399 0.03381 Cell differentiation Hypoxia
FGF13 0.0495 0.03781 Nervous system development, cell–cell signaling Hypoxia, mental retardation
MPZ 0.053 0.03781 Synaptic transmission, transmission of nerve impulse Ataxia, infantile hypotonia, hypotonia, mental retardation
MYO5A 0.052 0.03781 Ion transport Fragile X, hypotonia, mental retardation
PAX5 0.0533 0.03781 Cell differentiation Microcephaly
RPS6KA3 0.0503 0.03781 Nervous system development Ataxia, microcephaly, hypoxia, hypotonia, mental retardation
SLC1A3 0.0514 0.03781 Ion transport, synaptic transmission, transmission of nerve impulse Ataxia
TSPAN32 0.0498 0.03781 Cell–cell signaling Angelman syndrome
FOXG1 0.0571 0.03926 Brain development Microcephaly
PAX8 0.0577 0.03926 Cell differentiation Mental retardation
SIAH1 0.0619 0.04127 Cell differentiation Hypoxia
PHEX 0.0637 0.04164 Cell–cell signaling Hypotonia, mental retardation
ABCD1 0.0684 0.04385 Ion transport Hypotonia, spasticity
SLC11A2 0.0707 0.04447 Ion transport Ataxia, hypoxia
EDN2 0.0746 0.04489 Cell–cell signaling Hypoxia
EIF2B2 0.0781 0.04489 Nervous system development Ataxia, spasticity
ETFDH 0.078 0.04489 Ion transport Hypotonia, mental retardation
PMP22 0.0776 0.04489 Synaptic transmission, transmission of nerve impulse Ataxia, mental retardation, Infantile hypotonia, hypotonia, spasticity
RHOB 0.0741 0.04489 Cell differentiation Hypoxia
AMH 0.0835 0.04563 Cell–cell signaling Hypoxia
FLT1 0.0876 0.04563 Cell differentiation Hypoxia
GPI 0.0866 0.04563 Nervous system development Ataxia, hypoxia
GRIA3 0.0868 0.04563 Ion transport Seizure disorder, Rett syndrome, mental retardation
SIM2 0.085 0.04563 Cell differentiation, nervous system development Hypoxia, mental retardation
TTR 0.0847 0.04563 ion transport Ataxia, fragile X, major depression
Student t-test p values and FDR-based q values indicate signiﬁcance. The gene ontology biological processes and autism sibling disorders in which these genes are implicated are
listed. The complete list of 154 process-based candidates is available as online Supplementary Table 2.
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Fig. 3. Example of network-driven based strategy for identifying new autism gene candidates.
126 D.P. Wall et al. / Genomics 93 (2009) 120–129(NINDS) online database. NINDS treats disorders typically consid-
ered to be part of the Autism Spectrum Disorder as separate
disorders. To minimize biases in our analysis, we opted to retain
this circumscription “as-is”. As a consequence, throughout this
manuscript we use the term “autism” rather than “autism spectrum
disorder”. We then generated lists of candidate genes for each
disorder by taking the union of genes returned from OMIM [26] and
GeneCards [27]. A candidate is hereafter simply deﬁned as a gene
that is listed in either or both of these databases as associated with
the disease term. Candidates may be based on linkage studies in
families, linkage disequilibrium, or other sources (e.g. as described
in ftp://ftp.ncbi.nih.gov/repository/OMIM/genemap.key). We com-
puted the intersection of each disease gene list with the list for
autism and ranked the results in descending order of number of
shared genes. This allowed us to circumscribe a list of neurological
disorders with the greatest number of genes in common with
autism, resulting in a set of 40 diseases with possible molecular
similarities to autism.
Disease relationship tree
The seed lists provided by OMIM and GeneCards were combined
and transformed into a matrix of binary gene presence/absence with
respect to each disease. Thematrixwas then analyzed usingmaximum
parsimony in PAUP⁎ [28] to reconstruct the relationships among the
41 neurological disorders. Distance based clustering approaches
(neighbor joining and UPMGA) produced equivalent results.Molecular network reconstruction
For each disorder and associated gene list, we used STRING
(Search Tool for Retrieval of Interacting Genes/Proteins) version 6.3
[11], downloaded in December 2006, to construct networks from 5
separate lines of evidence: Conserved neighborhoods, Co-occur-
rence, Co-expression, Databases, and Text mining. The evidence
involves: (1) synteny derived from SwissProt and Ensembl, (2)
phylogenetic proﬁles derived from COG database [29,30], (3) co-
regulation of genes measured using microarrays imported from
ArrayProspector [31], (4) validated small-scale interactions, protein
complexes, and annotated pathways from BIND [32], KEGG [33] and
MIPS [34], and (5) co-mention of gene names from PubMed
abstracts. The networks were generated using the default settings
in STRING, with a medium conﬁdence score of 0.4. The lists of edges
returned for each disorder were then imported into a relational
database for subsequent analysis.
Biological process enrichment
Gene symbol identities corresponding to the PBC list were loaded
into the ExPlain™ 2.3 Tool (www.biobase-international.com), which
performs a Fisher's exact test to generate a p value for all biological
processes containing 2 or more genes. To account for multiple
testing, all p values were corrected using the Bonferroni adjustment
[35]; each p value was adjusted by the number of biological
processes in GO, which at the time of writing was 14648.
Table 4
The top 40 network-based candidates (NBC) sorted on the number of autism sibling disorders (see Fig. 1) in which the genes are implicated
Gene P value Q value MDAG interactor Disorders
CREBBP 0.0266 0.011509 SLC6A4 Ataxia, hypoxia, mental retardation
HPRT1 0.0353 0.012024 FMR1,ADSL Ataxia, fragile X, mental retardation
RPS6KB1 0.0402 0.012267 PTEN Ataxia, hypoxia, tuberous sclerosis
MYO5A 0.052 0.013362 FMR1 Fragile X, hypotonia, mental retardation
LAMA2 0.0557 0.013695 DCX Microcephaly, hypotonia, mental retardation
MAP1B 0.0561 0.013695 FMR1,FXR1,MAP2 Fragile X, tuberous sclerosis, mental retardation
HNRNPK 0.0577 0.013969 FMR1 Fragile X, hypoxia, mental retardation
TTR 0.0847 0.016765 APOE Ataxia, fragile X, major depression
GRIA3 0.0868 0.016897 NTF4 Seizure disorder, Rett syndrome, mental retardation
EIF4E 0.1003 0.018382 MAP2 Ataxia, hypoxia, tuberous sclerosis
ALAS2 0.108 0.019111 MAOA,SLC40A1 Ataxia, hypoxia, mental retardation
MTHFR 0.1179 0.020015 APOE Microcephaly, major depression, mental retardation
GH1 0.1297 0.021108 NF1 Seizure disorder, Hypoxia, mental retardation
PIK3R1 0.1459 0.023355 PTEN,TSC1,MET Ataxia, Hypoxia, tuberous sclerosis
DBH 0.149 0.023482 TPH1,MAOA,TH,TSC1 Major depression, tuberous sclerosis, mental retardation
CYFIP1 0.1764 0.024964 FMR1,FXR1 Angelman syndrome, fragile X, mental retardation
PTS 0.2004 0.026444 PTEN Seizure disorder, hypotonia, mental retardation
EDN3 0.2304 0.029733 ADSL,PAX3 Microcephaly, hypoxia, mental retardation
TFRC 0.2655 0.033006 SLC40A1,CD69 Ataxia, major depression, hypoxia
MAPK14 0.2887 0.034661 GLO1,GATA3 Ataxia, hypoxia, Rett syndrome
SLC6A8 0.296 0.034976 FMR1 Fragile X, hypotonia, mental retardation
TBX1 0.3729 0.041067 PAX3 Major depression, Asperger syndrome, mental retardation
ATL1 0.4141 0.044273 FMR1,GABRB3 Ataxia, mental retardation, spasticity
L1CAM 0.4366 0.046007 FMR1,MECP2,DCX Mental retardation, Rett syndrome, spasticity
ATM 0.0097 0.009728 PTEN Ataxia, microcephaly, hypoxia, mental retardation
OGDH 0.0062 0.009728 ABAT Hypoxia, Rett syndrome, hypotonia, mental retardation
PQBP1 0.013 0.009728 SLC6A4 Ataxia, microcephaly, mental retardation, spasticity
DMD 0.043 0.012724 DCX Hypoxia, infantile hypotonia, mental retardation
PSEN1 0.0519 0.013362 APOE Ataxia, major depression, hypoxia, spasticity
BDNF 0.0643 0.014489 MAP2,GRIN2A,NTF4,TH,SLC6A4 Major depression, hypoxia, Rett syndrome, mental retardation
FRAP1 0.0951 0.017973 PTEN,TSC1 Ataxia, seizure disorder, hypoxia, tuberous sclerosis
FLNA 0.2635 0.033006 DCX,TSC1 Microcephaly, hypoxia, tuberous sclerosis, mental retardation
NP 0.4431 0.046524 ADSL Ataxia, seizure disorder, hypotonia, spasticity microcephaly, mental retardation
PAFAH1B1 0.0092 0.009728 ARX,DAB1,DCX,TSC1 Tuberous sclerosis, hypotonia, spasticity microcephaly, seizure disorder
HADHA 0.0204 0.011078 ACADL Infantile hypotonia, hypotonia, mental retardation
RPS6KA3 0.0503 0.013362 ARX,GRPR Ataxia, microcephaly, hypoxia, hypotonia, mental retardation
RB1 0.0662 0.014495 PTEN,NF1 Ataxia, major depression, hypoxia, tuberous sclerosis, mental retardation
EMX2 0.1834 0.025706 DCX,TSC1 Microcephaly, mental retardation, tuberous sclerosis, hypotonia, spasticity
ATRX 0.3561 0.039603 SNRPN Ataxia, microcephaly, mental retardation, hypotonia, spasticity
SLC17A5 0.3569 0.039603 TH Ataxia, mental retardation, infantile hypotonia, hypotonia, spasticity
NBC genes are directly connected to a multi-disorder autism gene, but not yet implicated in autism. The MDAG gene(s) to which the NBC gene interacts is provided. Student t-test p
value and FDR-based q value are provided to indicate the extent towhich these genes are differentially regulated in autistic individuals when compared to controls. A total of 289 NBC
genes were found to be differentially expressed. A complete list of the NBC genes is available online in Supplementary Table 3.
Table 5
Enriched biological processes for 9 genes found by both the process-and network-based
analytical strategies
Gene ontology biological process P value Genes
Establishment of localization 1.02E-04 FLNA, SLC16A2, PAFAH1B1,
AR, MYO5A, OPHN1, FXN,
SLC6A8, FLNA, SLC16A2,
PAFAH1B1, AR, MYO5A
Localization 1.05E-04 OPHN1, FXN, SLC6A8
Nervous system development 0.001619529 FLNA, PAFAH1B1, L1CAM,
OPHN1
Cell organization and biogenesis 0.005608511 FLNA, PAFAH1B1, AR,
MYO5A, OPHN1
Locomotion 0.00673254 FLNA, PAFAH1B1, OPHN1
Localization of cell 0.00673254 FLNA, PAFAH1B1, OPHN1
Cell motility 0.00673254 FLNA, PAFAH1B1, OPHN1
Cytoskeleton organization and biogenesis 0.018371497 FLNA, PAFAH1B1, MYO5A
Cell communication 0.021262073 FLNA, PAFAH1B1, AR, OPHN1,
FXN, SLC6A8
Cell differentiation 0.028541906 PAFAH1B1, L1CAM, OPHN1
Cell–cell signaling 0.031948026 AR, FXN, SLC6A8
Transport 0.047207875 SLC16A2, AR, MYO5A, FXN,
SLC6A8
The p value is based on Fisher's exact test and was not corrected for multiple tests. All 9
genes occur in 3 or more autism sibling disorders and were found to be signiﬁcantly
differentially expressed in autistic patients.
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From Gene Expression Omnibus (GEO) we downloaded GSE6575
[16,36]. This dataset consisted of 17 samples of autistic patients
without regression, 18 patients with regression, 9 patients with
mental retardation or developmental delay, and 12 typically
developing children from the general population; total RNA was
extracted from whole blood samples using the PaxGene Blood RNA
System according the manufacturer's speciﬁcations and run on
Affymetrix U133plus2.0. For the purposes of the present study, we
elected to use only the 35 autistic patient samples and 12 control
samples from the general population. All preprocessing and
expression analyses were done with the Bioinformatics Toolbox
Version 2.6 (For Matlab R2007a+). GCRMA was used for background
adjustment and control probe intensities were used to estimate
non-speciﬁc binding [37]. Housekeeping genes, gene expression
data with empty gene symbols, genes with very low absolute
expression values and genes with a small variance across samples
were removed from the preprocessed dataset. We then conducted a
preliminary analysis to determine the difference in signal between
the two groups of autistic individuals, autistics with and without
regression (early onset autism). When compared to the 12 control
samples using a t-test, we learned that the p value distribution for
Fig. 4. The autism network redrawn in light of its intersectionwith the autism sibling disorders. Several obvious delineations are highlighted, namelyMental retardation, Angelman's
syndrome, and Rett syndrome.
128 D.P. Wall et al. / Genomics 93 (2009) 120–129the autistic patients with regression was ﬂat and therefore non-
informative. Thus, throughout the present study we used only the
17 samples from autistic individuals without regression (also
referred to as early onset autism). Correction for multiple tests
was done by calculating q values, a measure of signiﬁcant in terms
of the false discovery rate [38].Acknowledgment
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